ALFA Finder| Demand visibility | Targeting global markets across India, US, MENA, and SEA. |
|---|---|
| Management confidence | High regarding ecosystem integration and global scalability. |
Growth
No Q1 FY27 financial numbers or year-on-year growth percentages provided for Revenue or PAT.
Outlook
Focus on Made-in-India MRI (2025), scaling AI screening platforms globally, and hospital digitization.
Risks
Regulatory framework changes, technology cycles, market fluctuations, and potential inaccuracies in preliminary estimates.
Last quarter's promises, checked
Delivered
- Guided H1 FY26 revenue 120% growth → delivered INR 110cr (+120% YoY) (= BEAT)
- Guided H1 FY26 EBITDA margin expansion → delivered 25% margin (22x YoY growth) (= BEAT)
- Guided Q2 FY26 PAT growth → delivered INR 14cr (vs 0.3cr YoY) (= BEAT)
Partly delivered
- Guided commercial Nanomedic deployment in Nov 2025 → awaiting final CDSCO approval (= PARTIAL)
Investor Presentation filed with BSE, NSE: FISCHER. Summary written with AI assistance from the document.
Fischer Medical Ventures Ltd: key numbers
- Share price
- ₹25.13
- Market cap
- ₹1,741 Cr
- Revenue (annual)
- ₹308.6 Cr
- Net profit (annual)
- ₹31.02 Cr
- P/E (TTM)
- 58.4×Sector 35.5×
- Promoter holding
- 63.08%+0.93% QoQ
- FII holding
- 6.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fischer Medical Ventures Ltd
All →Fischer Medical Ventures Board Meeting Date
Fischer Medical Ventures has intimated a board meeting on 14 November 2026 to consider unaudited Q2 results. The trading window stays closed until 48 hours after results.
Fischer Medical Ventures Management Change
Fischer Medical Ventures appointed Mr. Chan Sing En as Independent Director of SG subsidiary FMV Global Innovations, effective 27 Oct 2026. No financial consideration involved.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures Ltd filed its quarterly shareholding pattern under Regulation 31. This routine disclosure presents the company's current ownership structure.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Ltd has issued a Postal Ballot Notice seeking shareholder approval for creating security on subsidiary assets and promoter share pledges for proposed NCD issuance.
Fischer Medical Ventures Board Meeting Outcome
Fischer Medical Ventures' board approved a postal ballot notice for RPT consent and borrowing limits, and appointed a scrutinizer. No material transaction or financial figure was decided at this meeting.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting via video conferencing on September 29, 2026, with the requisite quorum present.